GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Medical
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Location:
United States
Description:
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Language:
English
Curative Strategies for Patients with Smoldering Multiple Myeloma
Duración:00:03:05
Management of Bispecific Antibodies Side Effects
Duración:00:03:10
Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
Duración:00:06:03
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
Duración:00:03:02
Barriers to Biomarker Testing: Cost and Insurance
Duración:00:03:30
Barriers to Biomarker Testing: Ordering Tests
Duración:00:06:23
The Adaura Trial: The Effect on EGFR+ Treatment
Duración:00:06:26
Biomarker Driven Therapy for NSCLC
Duración:00:05:13
Current Recommendations and Best Practices for Biomarker Testing
Duración:00:03:53
The Importance of Biomarker Testing: What is Liquid Biopsy?
Duración:00:04:55
Biomarkers in NSCLC
Duración:00:05:55
Key Points from the Adaura Trial: Osimertinib
Duración:00:06:14
Biomarkers in NSCLC
Duración:00:05:55
The Importance of Biomarker Testing: What is Liquid Biopsy?
Duración:00:04:55
Barriers to Biomarker Testing: Cost and Insurance
Duración:00:03:30
Neoadjuvant Treatment for Patients with NSCLC
Duración:00:03:11
The Alina Trial for ALK+ NSCLC
Duración:00:01:13
Local Therapy for Limited Metastatic NSCLC
Duración:00:04:17
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
Duración:00:02:05
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
Duración:00:01:59